SCHEMBL1103044

SCHEMBL1103044

c1ccc(-c2cc3ccccc3cc2-c2c3ccccc3c(-c3ccccc3)c3ncccc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 6/20 0.45
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
CCR1 P32246 3/20 0.41
CCR8 P51685 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ESR1 P03372 4/20 0.41
ESR2 Q92731 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GMNN O75496 1/20 0.40
TP53 P04637 1/20 0.40
HSP90AA1 P07900 1/20 0.40
MMP2 P08253 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103010 0.95 TOP1 (0.46) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL1103146 0.92 TOP1 (0.41) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL1103203 0.89 TOP1 (0.41) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL1102988 0.88 CYP11B1 (0.50) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL13706310 0.87 TOP1 (0.44) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL13706351 0.85 TOP1 (0.43) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL1103122 0.85 CYP11B1 (0.51) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL1103085 0.84 CYP17A1 (0.42) TOP1LMNAMEN1HPGDKMT2A
SCHEMBL1102984 0.84 CKS1B (0.48) TOP1LMNACCR1CCR8L3MBTL1
SCHEMBL1103042 0.84 TOP1 (0.42) TOP1LMNACCR1CCR8L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 TOP1 4307/4885LMNA 2738/4885MEN1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.